Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

plications ("ANDAs") for generic versions of OFIRMEV; the potential that Cadence may be required to continue intellectual property litigation for substantial lengths of time or file additional lawsuits to defend its patent rights from challenges by companies that have submitted ANDAs for generic versions of OFIRMEV, and the substantial costs associated with such lawsuits; the potential introduction of generic competition to OFIRMEV in the event Cadence is unsuccessful in current or future intellectual property litigation; Cadence's dependence on its licensors for the maintenance and enforcement of its intellectual property rights; the potential product liability exposure associated with pharmaceutical products such as OFIRMEV and other products Cadence may in-license or acquire; Cadence's ability to fully comply with numerous federal, state and local laws and regulatory requirements that apply to its commercial activities; public concern regarding the safety of drug products such as OFIRMEV, which could result in the implementation by regulatory agencies of new requirements to include unfavorable information in the labeling for OFIRMEV; the risk that Cadence may not be able to raise sufficient capital when needed, or at all; and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the Securities and Exchange Commission from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Cadence® and OFIRMEV® are trademarks of Cadence Pharmaceuticals, Inc. Contact:

William R. LaRue

Kelli FranceSVP & Chief Financial Officer

Media RelationsCadence
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... developed a technique for controlling the surface tension of ... door to a new generation of reconfigurable electronic circuits, ... fact that the oxide "skin" of the metal ... a surfactant, lowering the surface tension between the metal ... liquid metal alloy of gallium and indium. In base, ...
(Date:9/15/2014)... idea of fibers made of carbon nanotubes is neat, but ... The single-walled carbon nanotubes in new fibers created at Rice ... process designed by chemist Angel Mart and his colleagues. , ... results this month in the journal ACS Nano , ... together into a fiber. , Left to their own devices, ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 Bioptigen ... deep imaging OCT system for the optical device metrology ... EnvisuTM S4410 SDOCT for Contact Lens Metrology ... standard and high complexity contact lens, IOL structures, and ... of a complete contact lens immersed in a hydration ...
(Date:9/15/2014)... Idaho , Sept. 15, 2014  iVinci Health ... only comprehensive Patient Revenue Management system, branded as VisitPay®, ... company also announced the launch of a new extension ... that provides an easy and convenient way for patients ... for balances owed by them and their families. ...
Breaking Biology Technology:Researchers control surface tension to manipulate liquid metals 2Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3
... BEIJING , Feb. 8 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. (the "Company") ... participate at the,following investor conferences in March 2010 : , , Investor Conference ... Location, Rodman & Renshaw Annual ... ...
... , Full enrollment occurs five months ahead of ... 8 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") ... Phase 2 clinical study of its lead drug RVX-208. "The ... full 5 months ahead of our original schedule, is a ...
... ... agency, announced today that it has been selected by Invida Group, the leading provider ... communications and public relations program. , ... Salem, MA (Vocus) February 8, 2010 -- LaVoie Group , ...
Cached Biology Technology:China Medical Technologies to Participate Investor Conferences in March 2010 2Resverlogix Completes Patient Recruitment for ASSERT Trial 2Resverlogix Completes Patient Recruitment for ASSERT Trial 3Resverlogix Completes Patient Recruitment for ASSERT Trial 4Invida Selects LaVoie Group as Public Relations Agency of Record 2Invida Selects LaVoie Group as Public Relations Agency of Record 3
(Date:9/15/2014)... is a vital source of energy for both plants ... its way into the cell could lead to the ... increase in the amount of fruits and vegetables farmers ... uncovered one of these "pathways" into the cell by ... a strand of spider silk. , To determine the ...
(Date:9/15/2014)... issue of the journal Science comes out, ... Montana and even the Netherlands, thanks to the type ... norm in these connected times. Yes, the research was ... in biology, medicine, biotechnology and agriculture. It could save ... that one, that one knew another one, and brilliant ...
(Date:9/15/2014)... reef ecologists fears that reef biodiversity may not provide ... once thought. , In an international study published today, ... for Coral Reef Studies (Coral CoE) says we need ... reef ecosystems. , In coral reefs, just as in ... the ecosystem safe and functioning. , Professor Bellwood ...
Breaking Biology News(10 mins):X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3Collaboration drives achievement in protein structure research 2Specialized species critical for reefs 2
... of infection in some hospital wards varies dramatically according ... A University of Leeds-led team studied airflow in a ... two rows of up to 30 bedsby using tracer ... found ventilation in the ward was generally good when ...
... CITY, Calif. , April 16, 2013   DigitalPersona, ... solutions, today announced that Papa John,s restaurants in ... fingerprint biometrics to speed and secure employees, and managers, ... in northern China are using ...
... April 16, 2013 Studies have shown that about ... (HIV) have an elevated resting energy expenditure (REE). Their ... body temperature, and breathing. Most studies have been conducted ... small sample sizes. A team of researchers has sought ...
Cached Biology News:Energy efficiency could increase infection risks in hospital wards 2Energy efficiency could increase infection risks in hospital wards 3Papa John's Restaurants in China Speed and Secure Workflow with DigitalPersona Fingerprint Biometrics 2Women with HIV shown to have elevated resting energy expenditure 2
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Bethyl Laboratories Epitope Retrieval Buffer-Reduced pH will unmask antigenic sites from formaldehyde fixation and allow for subsequent immunostaining. Shelf-Life: 1 year from date of receipt...
Mycoplasma and virus tested...
Mycoplasma and virus tested...
Biology Products: